menu

Beneficial effect of the SGLT2 inhibitor empagliflozin on HF-hospitalizations after acute MI

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations

Javed Butler at the ACC24
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    ACC.24 - Javed Butler shares the findings of the EMPACT-MI trial, in which empagliflozin had no effect on the primary endpoint in patients with acute MI but significant effect on HF hospitalizations.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Javed Butler, MD, is the President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health in Dallas, TX, US. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MI, US.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of EMPACT-MI trial

    Release date: 6 april 2024

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    ACC.24 - Javed Butler shares the findings of the EMPACT-MI trial, in which empagliflozin had no effect on the primary endpoint in patients with acute MI but significant effect on HF hospitalizations.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Javed Butler, MD, is the President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health in Dallas, TX, US. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MI, US.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of EMPACT-MI trial

    Release date: 6 april 2024

Facebook Comments

Schedule22 May 2024